Financial Contrast: Q Biomed (OTCMKTS:QBIO) and Agilon Health (NYSE:AGL)

Q Biomed (OTCMKTS:QBIO) and Agilon Health (NYSE:AGL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Valuation and Earnings

This table compares Q Biomed and Agilon Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	($0.02)	N/A
Agilon Health	$5.93 billion	0.32	-$391.35 million	($21.56)	-5.24

Q Biomed has higher earnings, but lower revenue than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Q Biomed and Agilon Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
Agilon Health	-6.09%	-146.03%	-24.55%

Analyst Ratings

This is a summary of recent ratings for Q Biomed and Agilon Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
Agilon Health	2	8	5	0	2.20

Agilon Health has a consensus price target of $58.73, indicating a potential downside of 48.06%. Given Q Biomed’s higher possible upside, analysts clearly believe Q Biomed is more favorable than Agilon Health.

Summary

Q Biomed beats Agilon Health on 5 of the 8 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About Agilon Health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.